Long-term Treatment Outcome for Stage III Nasopharyngeal Carcinoma Patients and Risk Grouping by Plasma Epstein-Barr Virus DNA
试验速览
- 阶段
- 不适用
- 状态
- 已完成
- 入组人数
- 366
- 主要终点
- Overall survival (OS)
研究概览
简要总结
No previous study reported the treatment outcome of stage III nasopharyngeal carcinoma (NPC) patients. The investigators try to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma Epstein-Barr virus (EBV) DNA assay for future therapy improvement.
详细描述
The stage III NPC patients were the majority group of the patient population of NPC. But most clinical trials focused on the treatment of American Joint Committee on Cancer (AJCC) 7th edition stage IVA/IVB treatment for high risk of recurrence or metastasis. No previous study reported the treatment outcome of stage III NPC patients. The investigators tried to investigate the long-term treatment outcome of stage III NPC patients and do risk grouping by plasma EBV DNA assay for future therapy improvement.
研究设计
- 研究类型
- Observational
- 观察模型
- Cohort
- 时间视角
- Retrospective
入排标准
- 年龄范围
- 20 Years 至 80 Years（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Biopsy-proven stage III nasopharyngeal carcinoma (NPC)
- •Finished curative chemoradiotherapy
- •Have Pre-treatment and post-radiotherapy plasma EBV DNA
排除标准
- •No tissue proven NPC
- •Not finished curative treatment
- •No Pre-treatment and post- radiotherapy plasma EBV DNA
结局指标
主要结局
Overall survival (OS)
时间窗: 5 year
Diagnosis to death
次要结局
- Locoregional failure-free survival (LRFFS)(5 year)
- Progression-free survival (PFS)(5 year)
- Distant metastasis failure-free survival (DMFFS)(5 year)